BiotechTube

AZD5148 + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridioides Difficile Infection

Conditions

Clostridioides Difficile Infection

Trial Timeline

Oct 31, 2024 → Dec 25, 2025

NCT ID
NCT06639997

About AZD5148 + Placebo

AZD5148 + Placebo is a phase 1 stage product being developed by AstraZeneca for Clostridioides Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT06639997. Target conditions include Clostridioides Difficile Infection.

What happened to similar drugs?

0 of 4 similar drugs in Clostridioides Difficile Infection were approved

Approved (0) Terminated (1) Active (3)
🔄C.difficile vaccinePfizerPhase 3
❌Ridinilazole + VancomycinSummit TherapeuticsPhase 3
🔄Ridinilazole + VancomycinSummit TherapeuticsPhase 3
🔄SER-109Seres TherapeuticsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06639997Phase 1Completed
NCT06469151Phase 1Completed

Competing Products

7 competing products in Clostridioides Difficile Infection

See all competitors
ProductCompanyStageHype Score
AZD5148AstraZenecaPhase 2
42
C.difficile vaccinePfizerPhase 3
47
Ridinilazole + VancomycinSummit TherapeuticsPhase 3
29
Ridinilazole + VancomycinSummit TherapeuticsPhase 3
37
REC-3964Recursion PharmaceuticalsPhase 2
21
SER-109Seres TherapeuticsPre-clinical
16
SER-109Seres TherapeuticsPhase 3
30